RxDoctor Payments Data

Steven Heifetz, MD

Cardiovascular Disease · Edina, MNNPI 1497732804

Payments from drug & device makers

$9,026in general payments, 2019–2025

Across 91 payments — averaging $99.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osprey Medical Inc$3K
  • Abbott$2K
  • Medtronic$2K
  • Boston Scientific$1K
  • Abiomed$403
  • Teleflex LLC$148
  • plus $441 from 5 others
$3,200in research payments, 2019–2025

Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$3K

What the payments were for

  • Consulting fees$4,50050%
  • Travel & lodging$1,97522%
  • Food & beverage$2,52728%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Osprey Medical Inc1$3,000
Abbott12$2,444
Medtronic1$1,500
Boston Scientific66$1,090
Abiomed3$403
Teleflex LLC1$148
ZOLL Circulation Inc1$142
Edwards Lifesciences2$137
Corindus Inc.1$118
Chiesi USA, Inc.2$24
Philips North America LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,026 in reported general payments places this provider in the 60th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$92,421
Medicare patients
553
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$114,662
XareltoRivaroxaban18$26,855
Repatha SureclickEvolocumab16$23,095
EntrestoSacubitril/Valsartan20$22,578
JardianceEmpagliflozin18$20,109
BrilintaTicagrelor22$16,039
Praluent PenAlirocumab12$11,393
Atorvastatin Calcium221$4,213
Metoprolol Succinate149$3,263
Nebivolol Hcl61$2,689
Rosuvastatin Calcium125$2,093
Ranolazine ErRanolazine20$1,786
ClopidogrelClopidogrel Bisulfate101$1,689
Ezetimibe68$1,654
Isosorbide Mononitrate ErIsosorbide Mononitrate76$1,648

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →